Home :: Medication :: Betaseron

Latest Betaseron News

Chiron Reports 2005 Adjusted Earnings of $1.34 Per Share, GAAP ... - Business Wire (press release)

CHIRON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended December 31, -------------------------------------- 2005 -------------------------------------- Adjusted (1) Adjustments Actual ------------ ------------ ------------ Revenues: Product Sales, net $ 475,267 $ - $ 475,267 Revenues from joint Business arrangement 33,547 - 33,547 Collaborative agreement revenues 1,955 - 1,955 Royalty and license fee revenues 89,697 - 89,697 Other revenues 15,173 - 15,173 ------------ ------------ ------------ Total revenues 615,639 - 615,639 ------------ ------------ ------------ Operating expenses: Cost of Sales 215,116 - 215,116 Research and development 109,271 - 109,271 Selling, general and administrative 125,777 - 125,777 Amortization expense - (11,969) 11,969 Impairment loss on acquired intangible assets - (1,136) 1,136 Other operating expenses 7,692 - 7,692 ------------ ------------ ------------ Total operating expenses 457,856 (13,105) 470,961 ------------ ------------ ------------ Income (loss) from operations 157,783 13,105 144,678 Loss on disposal of assets (319) - (319) Interest expense (7,683) - (7,683) Interest and other income, net 19,644 - 19,644 Minority interest (498) - (498) ------------ ------------ ------------ Income (loss) from continuing operations before income taxes 168,927 13,105 155,822 Provision for (benefit of) income taxes 5,085 (6,552) 11,637 ------------ ------------ ------------ Income (loss) from continuing operations 163,842 19,657 144,185 ============ ============ ============ - More available

Betaseron

No Ebay Marketplace Listings Found